BioSpace News Archive

Domrex Pharma Inc., a leading manufacturer and distributor of medical supplies in Canada, is thrilled to announce the acceleration of its expansion into the United States.

Fractyl Health announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health.

The Board of Acarix AB (publ) announces the immediate appointment of Aamir Mahmood as its new CEO, effective February 1.

FORE Biotherapeutics today announced that the Company, will participate at the following investor conferences.

Proniras Corporation (“Proniras”) today announced the successful completion of a $4.65 million funding round, marking a significant milestone in its ongoing Series B financing, which aims to secure up to $9 million.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”) today announced the signing of an exclusive long-term license agreement with BIRAD, a research & development company of Bar-Ilan University, to use the joint patent it has with BIRAD for innovative cocaine treatment.

Synchron today announced the acquisition of an equity stake in ACQUANDAS, a leading technology provider specializing in state-of-the-art high-precision components for the healthcare industry and other industries.

Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique.

Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release fourth quarter 2023 results on Tuesday, February 20, 2024, after the market closes.

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA.